SH3GL2 and prostate adenocarcinoma: Apart from GBM, SH3GL2 deviation was marked in the kidney chromophobe tumor (KICH), kidney renal cell carcinoma (KIRC), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), and sarcoma (SARC).